Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Lidocaine Injection Before TORS and Neck Dissection for HPV-Associated OPSCC
NCT06747390Phase 1Recruiting
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of lidocaine in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms). Primary endpoints: Safety measured by occurrence of adverse events at 2 years and Pathological tumor response at 2 years. Started Apr 2025; status: recruiting.
02
Drugs
lidocaine
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06747390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747390.